Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2020 1
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, Batlevi CL, Campbell P, Ribrag V, Damaj GL, Dickinson M, Jurczak W, Kazmierczak M, Opat S, Radford J, Schmitt A, Yang J, Whalen J, Agarwal S, Adib D, Salles G. Morschhauser F, et al. Among authors: adib d. Lancet Oncol. 2020 Nov;21(11):1433-1442. doi: 10.1016/S1470-2045(20)30441-1. Epub 2020 Oct 6. Lancet Oncol. 2020. PMID: 33035457 Free PMC article. Clinical Trial.
Molecular Monitoring of Knockdown Resistance in Head Louse (Phthiraptera: Pediculidae) Populations in Iran.
Ghahvechi Khaligh F, Djadid ND, Farmani M, Asadi Saatlou Z, Frooziyan S, Abedi Astaneh F, Farnoosh F, Sofizadeh A, Naseri F, Adib D, Taheri M, Lalehzari E, Pashaei S, Soltanbeiglou S, Soltani A, Khooban H, Abbasi E, Aivazi AA, Saeedi S, Taghilou B, Jafari A, Dashti Khavidak K, Toloza AC, Gholizadeh S. Ghahvechi Khaligh F, et al. Among authors: adib d. J Med Entomol. 2021 Nov 9;58(6):2321-2329. doi: 10.1093/jme/tjab101. J Med Entomol. 2021. PMID: 34106252
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
Proudman D, Nellesen D, Gupta D, Adib D, Yang J, Mamlouk K. Proudman D, et al. Among authors: adib d. Adv Ther. 2022 Apr;39(4):1678-1696. doi: 10.1007/s12325-022-02054-z. Epub 2022 Feb 14. Adv Ther. 2022. PMID: 35157216 Free PMC article.